Can a Breath-Activated inhaler match the standard for asthma control?

NCT ID NCT03453112

Completed Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether a breath-activated dry powder inhaler (NEXThaler) delivers the same asthma control as a traditional pressurized inhaler (pMDI), both containing the same combination of medications (beclometasone and formoterol). Adults with well-controlled asthma will use one of the two devices twice daily for 12 weeks. Researchers will measure morning peak flow to see if the two devices perform equally well, along with other lung function and safety checks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A fixed combination of beclometasone dipropionate (an inhaled corticosteroid) and formoterol fumarate (a long-acting bronchodilator), delivered via two different inhaler devices.
What this could lead to: If the breath-actuated inhaler works as well as the traditional one, it could offer people with asthma a more convenient and reliable way to take their daily controller medication.
What could go wrong: This is a non-inferiority trial, so it aims to show the new device is not worse than the existing one, not that it is better. Results may not apply to all asthma patients, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Chiesi Clinical Trial site 15607

Zhanjiang, Guangdong, 524001, China
Chiesi Clinical Trial site 15608

Shenzhen, Guangdong, China
Chiesi Clinical Trial site 15610

Guangzhou, Guangzhou, 511400, China
Chiesi Clinical Trial site 15611

Shijiazhuang, Shijiazhuang, 050000, China
Chiesi Clinical Trial site 15614

Wuhan, Hubei, 430030, China
Chiesi Clinical Trial site 15625

Taiyuan, Shanxi, 030001, China
Chiesi Clinical Trial site 15626

Xi'an, Xian, 710061, China
Chiesi Clinical Trial site 15628

Shanghai, China
Chiesi Clinical Trial site 15630

Shanghai, Shanghai Municipality, 200025, China
Chiesi Clinical Trial site 15630

Shanghai, Shanghai Municipality, China
Chiesi Clinical Trial site 15631

Shanghai, Shanghai Municipality, China
Chiesi Clinical Trial site 15633

Chengdu, Sichuan, 610041, China
Chiesi Clinical Trial site 15634

Tianjin, Tianjin Municipality, 300350, China
Chiesi Clinical Trial site 15638

Chongqing, China
Chiesi Clinical Trial site 15641

Hefei, Anhui, China
Chiesi Clinical Trial site 15642

Tianjin, Tianjin Municipality, 300052, China
Chiesi Clinical Trial site 15643

Changzhou, Jiangsu, 213164, China
Chiesi Clinical Trial site 15650

Hohhot, Neimenggu, 010017, China
Chiesi Clinical Trial site 15654

Shanghai, Shanghai Municipality, 201100, China
Chiesi Clinical Trial site 15661

Wuhan, Hubei, China
Chiesi Clinical Trial site 15662

Foshan, Guangdong, China
Chiesi Clinical Trial site 15663

Beijing, Beijing Municipality, 101100, China
Chiesi Clinical Trial site 15664

Shanghai, Shanghai Municipality, 200050, China
Chiesi Clinical Trial site 15665

Shanghai, Shanghai Municipality, China
Chiesi Clinical Trial site 15666

Shenzhen, China
Chiesi Clinical Trial site 15668

Guangzhou, Guangdong, China
Chiesi Clinical Trial site 15669

Ürümqi, 830054, China
Chiesi Clinical Trial site 15670

Guizhou, China
Chiesi Clinical Trial site 15671

Guangzhou, Guangdong, 5100150, China
Chiesi Clinical Trial site 15672

Beijing, 100144, China
Chiesi Clinical Trial site 15673

Haikou, Hainan, 570208, China
Chiesi Clinical Trial site 15674

Pingxiang, Jiangxi, 337055, China
Chiesi Clinical Trial site 15675

Hengyang, Hunan, 421000, China
Chiesi Clinical Trial site 15676

Jilin City, Jilin, 132011, China
Chiesi Clinical Trial site 15677

Huizhou, Guangdong, 516001, China
Chiesi Clinical Trial site 15678

Qiqihar, Heilongjiang, 161002, China
Chiesi Clinical Trial site 15679

Zhengzhou, Henan, 450003, China
Chiesi Clinical Trial site 15680

Chongqing, Sichuan, 408499, China
Chiesi Clinical Trial site 15681

Xinxiang, Henan, 453000, China
Chiesi Clinical Trial site 15682

Beijing, Beijing Municipality, 100000, China
Chiesi Clinical Trial site 15683

Shenzhen, Guangdong, 518052, China
Chiesi Clinical trial site 15660

Jilin City, China
Chiesi clinical Trial Site 15610

Guangzhou, Guangdong, 510120, China
Chiesi clinical Trial Site 15611

Hebei, China
Chiesi clinical Trial site 15619

Nanchang, Nanchang, 330006, China
Chiesi clinical Trial site 15621

Shenyang, Liaoning, China
Chiesi clinical Trial site 15633

Sichuan, China
Chiesi clinical Trial site 15636

Beijing, China
Chiesi clinical Trial site 15656

Guangzhou, Guangdong, China
Chiesi clinical Trial site 15659

Hohhot, Neimenggu, China
Chiesi clinical trial site 15637

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.